Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 274

1.

Synthesis and biochemical characterization of EGF receptor in a water-soluble membrane model system.

Scharadin TM, He W, Yiannakou Y, Tomilov AA, Saldana M, Cortopassi GA, Carraway KL 3rd, Coleman MA, Henderson PT.

PLoS One. 2017 Jun 6;12(6):e0177761. doi: 10.1371/journal.pone.0177761. eCollection 2017.

2.

Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways.

Wee P, Wang Z.

Cancers (Basel). 2017 May 17;9(5). pii: E52. doi: 10.3390/cancers9050052. Review.

3.

The development of bispecific antibodies and their applications in tumor immune escape.

Zhang X, Yang Y, Fan D, Xiong D.

Exp Hematol Oncol. 2017 May 2;6:12. doi: 10.1186/s40164-017-0072-7. eCollection 2017. Review.

4.

Molecular Signaling of Progesterone, Growth Hormone, Wnt, and HER in Mammary Glands of Dogs, Rodents, and Humans: New Treatment Target Identification.

Timmermans-Sprang EPM, Gracanin A, Mol JA.

Front Vet Sci. 2017 Apr 13;4:53. doi: 10.3389/fvets.2017.00053. eCollection 2017. Review.

5.

Targeted therapies in breast cancer: New challenges to fight against resistance.

Masoud V, Pag├Ęs G.

World J Clin Oncol. 2017 Apr 10;8(2):120-134. doi: 10.5306/wjco.v8.i2.120. Review.

6.

Pseudoscaffolds and anchoring proteins: the difference is in the details.

Aggarwal-Howarth S, Scott JD.

Biochem Soc Trans. 2017 Apr 15;45(2):371-379. doi: 10.1042/BST20160329. Review.

7.

Human Epidermal Growth Factor Receptor-3 mRNA Expression as a Prognostic Marker for Invasive Duct Carcinoma not Otherwise Specified.

Hammoda GE, El-Hefnawy SM, Abdou AG, Abdallah RA.

J Clin Diagn Res. 2017 Feb;11(2):XC01-XC05. doi: 10.7860/JCDR/2017/23812.9442. Epub 2017 Feb 1.

8.

Affibody molecules as engineered protein drugs.

Frejd FY, Kim KT.

Exp Mol Med. 2017 Mar 24;49(3):e306. doi: 10.1038/emm.2017.35. Review.

9.

Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.

Huang Y, Burns DJ, Rich BE, MacNeil IA, Dandapat A, Soltani SM, Myhre S, Sullivan BF, Lange CA, Furcht LT, Laing LG.

BMC Cancer. 2017 Mar 16;17(1):199. doi: 10.1186/s12885-017-3181-0.

10.

Effects of ErbB2 Overexpression on the Proteome and ErbB Ligand-specific Phosphosignaling in Mammary Luminal Epithelial Cells.

Worthington J, Spain G, Timms JF.

Mol Cell Proteomics. 2017 Apr;16(4):608-621. doi: 10.1074/mcp.M116.061267. Epub 2017 Feb 7.

11.

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition.

Ortiz-Zapater E, Lee RW, Owen W, Weitsman G, Fruhwirth G, Dunn RG, Neat MJ, McCaughan F, Parker P, Ng T, Santis G.

PLoS One. 2017 Jan 31;12(1):e0170798. doi: 10.1371/journal.pone.0170798. eCollection 2017.

12.

EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma.

Chan E, Alkhasawneh A, Duckworth LV, Aijaz T, Toro TZ, Lu X, Hughes SJ, Collinsworth A, George TJ Jr.

J Gastrointest Oncol. 2016 Dec;7(6):838-847. doi: 10.21037/jgo.2016.06.09.

13.

LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer.

Takahashi S, Kobayashi T, Tomomatsu J, Ito Y, Oda H, Kajitani T, Kakizume T, Tajima T, Takeuchi H, Maacke H, Esaki T.

Cancer Chemother Pharmacol. 2017 Jan;79(1):131-138. doi: 10.1007/s00280-016-3214-4. Epub 2016 Dec 9.

14.

IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation.

Ikink GJ, Boer M, Bakker ER, Hilkens J.

Nat Commun. 2016 Nov 23;7:13567. doi: 10.1038/ncomms13567.

15.

Human epidermal growth factor receptor 4 (HER4) is a favorable prognostic marker of breast cancer: a systematic review and meta-analysis.

Wang J, Yin J, Yang Q, Ding F, Chen X, Li B, Tian X.

Oncotarget. 2016 Nov 22;7(47):76693-76703. doi: 10.18632/oncotarget.12485.

16.

Neuregulin 1 Regulates Proliferation of Leydig Cells to Support Spermatogenesis and Sexual Behavior in Adult Mice.

Umehara T, Kawashima I, Kawai T, Hoshino Y, Morohashi KI, Shima Y, Zeng W, Richards JS, Shimada M.

Endocrinology. 2016 Dec;157(12):4899-4913. Epub 2016 Oct 12.

PMID:
27732090
17.

A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity.

Huang Y, Burns DJ, Rich BE, MacNeil IA, Dandapat A, Soltani SM, Myhre S, Sullivan BF, Furcht LT, Lange CA, Hurvitz SA, Laing LG.

Oncotarget. 2016 Nov 29;7(48):78577-78590. doi: 10.18632/oncotarget.12480.

18.

Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung.

Shin DH, Lee D, Hong DW, Hong SH, Hwang JA, Lee BI, You HJ, Lee GK, Kim IH, Lee YS, Han JY.

Oncotarget. 2016 Oct 25;7(43):69450-69465. doi: 10.18632/oncotarget.11913.

19.

HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status.

Weitsman G, Barber PR, Nguyen LK, Lawler K, Patel G, Woodman N, Kelleher MT, Pinder SE, Rowley M, Ellis PA, Purushotham AD, Coolen AC, Kholodenko BN, Vojnovic B, Gillett C, Ng T.

Oncotarget. 2016 Aug 9;7(32):51012-51026. doi: 10.18632/oncotarget.9963.

20.

Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer.

Sforza V, Martinelli E, Ciardiello F, Gambardella V, Napolitano S, Martini G, Della Corte C, Cardone C, Ferrara ML, Reginelli A, Liguori G, Belli G, Troiani T.

World J Gastroenterol. 2016 Jul 28;22(28):6345-61. doi: 10.3748/wjg.v22.i28.6345. Review.

Supplemental Content

Support Center